Patient subgroups may benefit, suggest some findings from the sham-controlled trial, at least the third major study of the controversial procedure. Further studies are warranted, says an observer.
Medscape Medical News
This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.